Research Training in Pediatric Oncology

描述（由申请人提供）：这是一份竞争性更新申请，用于儿科肿瘤学培训资助支持。T32项目的目标是培养未来在基础和/或临床儿科肿瘤研究领域的学术领袖，并致力于减轻儿科人群癌症负担的医生。为了实现这一目标，我们聘请了一支多元化的优秀培训师资队伍，包括基础研究（“湿凳”）、转化研究和临床研究等多个领域。这个经验丰富、成就卓著的小组包括丹娜-法伯癌症研究所（DFCI）儿科肿瘤科、波士顿儿童医院（BCH）儿科血液学/肿瘤科以及哈佛医学院（HMS）的其他组成部分的成员。特别强调的是在选择导师和在研究期间进行监督时对受训者进行密切指导。T32项目为8名从DFCI-BCH儿童血液学/肿瘤学联合奖学金项目中选出的二、三、四年的受研者提供博士后水平的肿瘤研究培训。该项目致力于发现和支持最有前途的研究员，包括少数族裔候选人。在过去的45年里，DFCI-BCH奖学金项目已经培训了200多人，其中许多人是儿科血液学/肿瘤学学术项目的领导者。T32的持续支持将确保对研究性儿科肿瘤学家的培训，他们的研究将对儿童癌症的理解和管理做出不可估量的贡献。

DESCRIPTION (provided by applicant): This is a competitive renewal application for training grant support in pediatric oncology. The goal of this T32 program is to train physicians who will be the future academic leaders in basic and/or clinical pediatric oncology research and who will work to reduce the burden of cancer in the pediatric population. To accomplish this goal we have engaged a diverse and outstanding training faculty that embraces multiple areas of basic ("wet bench"), translational and clinical research. This experienced and highly accomplished group includes members of the Department of Pediatric Oncology at the Dana-Farber Cancer Institute (DFCI), the Division of Pediatric Hematology/Oncology at Boston Children's Hospital (BCH), and additional components of the Harvard Medical School (HMS). Particular emphasis is placed on close mentorship of trainees in the selection of mentors and in on-going oversight during their research. The T32 program provides training in oncology research at the postdoctoral level for 8 trainees, selected from the combined DFCI-BCH pediatric hematology/oncology fellowship program, who are in their second, third and fourth years of training. The program is committed to identifying and supporting the most promising fellows, including minority candidates. Over the past 45 years the DFCI-BCH fellowship program has trained over 200 individuals, many of whom are leaders of academic pediatric hematology/oncology programs. Continued T32 support will ensure the training of investigational pediatric oncologists, whose research will contribute immeasurably to the understanding and management of childhood cancers.